Introduction
Lung cancer has long been one of the deadliest cancers worldwide, but not all lung cancers are the same disease at the molecular level. In roughly 15% of non-small cell lung cancer (NSCLC) cases, the most common form, accounting for about 85% of all lung cancer diagnoses, the tumor's growth is driven by mutations in a gene called EGFR (epidermal growth factor receptor). Finding those patients required something that didn't used to be routine: molecular testing of a patient's own tumor tissue, or increasingly, their blood.
Why the Samples Were Essential
Before targeted therapy existed, lung cancer treatment was largely one-size-fits-all chemotherapy, regardless of what was actually driving a tumor's growth. That changed once scientists began sequencing tumor samples and discovering that certain mutations, specifically, EGFR exon 19 deletions and exon 21 L858R substitutions, caused the receptor to send constant "grow" signals to cancer cells. Patients carrying these mutations could be matched to drugs designed to block that exact signal.
Tagrisso (osimertinib) is only prescribed for patients whose tumors harbor EGFR exon 19 deletion or exon 21 L858R mutations, as detected by an FDA-approved test, with molecular confirmation required before treatment begins across adjuvant, locally advanced, and metastatic settings alike.
That requirement makes the biopsy sample the gatekeeper of the entire treatment pathway. Originally, this meant a tissue biopsy. A physical tumor sample removed surgically or via needle. But tumors evolve, and patients on EGFR-targeted therapy eventually develop resistance, often through a secondary mutation called T790M. Instead of repeated invasive biopsies, researchers developed liquid biopsy: testing cell-free tumor DNA shed into a patient's bloodstream. Molecular characterization of advanced adenocarcinoma is now mandatory to identify alterations with available targeted therapies, and liquid biopsy has become a routine alternative or complement to tissue testing. Studies have found overall tissue-liquid concordance for EGFR alterations of 94%, meaning a simple blood draw can now reliably catch the same mutations that once required cutting tissue out of a tumor.
Liquid biopsy's value goes beyond diagnosis…it monitors treatment in real time. Research has shown that molecular progression detected in blood samples occurred on average 42 days prior to clinical progression visible on a scan, and the technology can also detect T790M, the predominant resistance mutation to first- and second-generation EGFR-TKIs, occurring in roughly half of patients who progress on earlier-generation therapy. That resistance insight is precisely what led to osimertinib's original development. It was designed as a third-generation EGFR-TKI capable of targeting tumors that had become resistant to earlier drugs via T790M.
The Result
The FDA originally approved Tagrisso in 2015 under accelerated approval for this resistant patient population. It has since expanded dramatically: Tagrisso has been used to treat more than one million patients across its indications worldwide, and is approved in more than 120 countries across multiple indications, spanning adjuvant, locally advanced, and first-line metastatic EGFR-mutated NSCLC. From one mutation to a treatment. backbone.
The UPDATE
Recent trial data continues to reinforce that Tagrisso's value is inseparable from biomarker testing. The Phase III FLAURA2 trial showed Tagrisso plus chemotherapy reduced the risk of disease progression or death by 38% and delivered a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer. More recently, the SAFFRON and SANOVO Phase III trials tested Tagrisso alongside a MET inhibitor (Orpathys) for patients whose tumors show MET overexpression, another biomarker-driven refinement that one trial investigator noted underscores "the urgency of MET testing to inform treatment decisions."
Commercially, the backbone status shows in the numbers: Tagrisso generated $7,254 million in revenue, up 10%, continuing as AstraZeneca's leading tyrosine kinase inhibitor and backbone therapy for EGFR-mutated NSCLC across multiple stages.
Why this Matters for the Biosample Story:
Every Tagrisso prescription traces back to a molecular test — tissue or blood — that identified a specific mutation in a specific gene. It's a therapy that exists only because scientists treated tumor samples not as a single diagnosis, but as a map of exactly which drug would work, and later, which new mutation meant it was time to switch. The sample isn't just how you find the cancer; with liquid biopsy, it's how you watch the treatment work in real time, weeks before a scan would tell you anything at all.








Leave a Reply